Bioabsorbable polymer-coated sirolimus-eluting stent implantation preserves coronary vasomotion: A DESSOLVE II trial sub-study.
Rusinaru D, Vrolix M, Verheye S, Chowdhary S, Schoors D, Di Mario C, Desmet W, Donohoe DJ, Ormiston JA, Knape C, Bezerra H, Lansky A, Wijns W; DESSOLVE II Investigators.
Catheter Cardiovasc Interv. 2015 Dec 1;86(7):1141-50. doi: 10.1002/ccd.25610. Epub 2015 Sep 22.
Twilight-specific light cues.
Tarantini G, Fraccaro C.
Catheter Cardiovasc Interv. 2021 Jan 1;97(1):72-73. doi: 10.1002/ccd.29443.
A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial.
de Winter RJ, Katagiri Y, Asano T, Milewski KP, Lurz P, Buszman P, Jessurun GAJ, Koch KT, Troquay RPT, Hamer BJB, Ophuis TO, Wöhrle J, Wyderka R, Cayla G, Hofma SH, Levesque S, Żurakowski A, Fischer D, Kośmider M, Goube P, Arkenbout EK, Noutsias M, Ferrari MW, Onuma Y, Wijns W, Serruys PW.
Lancet. 2018 Feb 3;391(10119):431-440. doi: 10.1016/S0140-6736(17)33103-3. Epub 2017 Dec 5.
Elastic stent recoil in coronary total occlusions: Comparison of durable-polymer zotarolimus eluting stent and ultrathin strut bioabsorbable-polymer sirolimus eluting stent.
Improta R, Scarparo P, Wilschut J, Wolff Q, Daemen J, Den Dekker WK, Zijlstra F, Van Mieghem NM, Diletti R.
Catheter Cardiovasc Interv. 2022 Jan 1;99(1):88-97. doi: 10.1002/ccd.29739. Epub 2021 May 7.
[Optimal platelet inhibition after coronary stent implantation. Current status].
Silber S, Hoffmeister HM, Bode C.
Herz. 2008 Jun;33(4):244-53. doi: 10.1007/s00059-008-3138-9.
The relation of polymer structure of stent used in patients with acute coronary syndrome revascularized by stent implantation with long-term cardiovascular events.
Yaylak B, Polat F, Onuk T, Akyüz Ş, Çalık AN, Çetin M, Eren S, Mollaalioğlu F, Kolak Z, Durak F, Dayı ŞÜ.
Catheter Cardiovasc Interv. 2023 Dec;102(7):1186-1197. doi: 10.1002/ccd.30881. Epub 2023 Oct 19.
Safety and efficacy of Everolimus-Eluting bioabsorbable Polymer-Coated stent in patients with long coronary lesions: The EVOLVE 48 study.
Karmpaliotis D, Stoler R, Walsh S, El-Jack S, Potluri S, Moses J, Oldroyd K, Banning A, Webster M, Zaman A, Wu W, Ahmed M, Underwood P, Allocco D.
Catheter Cardiovasc Interv. 2022 Feb;99(2):373-380. doi: 10.1002/ccd.29798. Epub 2021 May 29.
Coronary artery perforation after bioresorbable scaffold implantation treated with a new generation covered stent-OCT insights.
Chen D, Gadeley R, Wang A, Jepson N.
BMC Cardiovasc Disord. 2022 Feb 23;22(1):66. doi: 10.1186/s12872-022-02501-3.
Targeted therapy with a localized abluminal groove low-dose sirolimus-eluting bioabsorbable polymer coronary stent in chronic total occlusions: The TARGET CTO non-inferiority randomized trial.
Wang G, Zhang R, Chen SL, Wang J, Li Y, Zheng M, Cao R, Ma Y, Sun Z, Li X, Su X, Lu W, Xu Y, Li X, Li Y, Sun F, Han Y; TARGET CTO Investigators.
Am Heart J. 2025 Jul;285:93-104. doi: 10.1016/j.ahj.2025.01.018. Epub 2025 Feb 3.
Bioabsorbable drug-eluting vascular scaffold for the treatment of coronary in-stent restenosis: A two center registry.
Moscarella E, Varricchio A, Stabile E, Franzone A, Granata F, Rapacciuolo A, Galasso G, Capozzolo C, Cirillo P, Monda V, Monterforte I, Borgia F, Piro O, Bonzani G, Trimarco B, Esposito G.
Cardiovasc Revasc Med. 2015 Oct-Nov;16(7):401-5. doi: 10.1016/j.carrev.2015.07.008. Epub 2015 Aug 10.
